Literature DB >> 32459508

Buformin increases radiosensitivity in cervical cancer cells via cell-cycle arrest and delayed DNA-damage repair.

Ling Chen1,2, Ting Zhang1,2, Qiuli Liu2, Mei Tang1,2, Yu'e Yang1,2, Yuan Wang1,2, Haifeng Qiu3, Jinjin Yu1,2.   

Abstract

IMPACT STATEMENT: Our idea originated in the thought of discovering new effects of old drugs. Although this study is a basic research, it is very close to clinical treatment. Flow cytometry and immunofluorescence were used to verify that buformin increases radiosensitivity. We aimed to address one of the thorniest problems in treatment process. Based on discovering new effects of old drugs, it is feasible to use buformin as an anticancer drug in clinical application. This will provide new ideas for clinical treatment.

Entities:  

Keywords:  Cervical cancer; DNA damage; buformin; cell cycle arrest; radiosensitivity

Year:  2018        PMID： 32459508      PMCID： PMC6327368          DOI： 10.1177/1535370218813320

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


  19 in total

1.  Buformin-induced lactic acidosis--a symptom of modern healthcare malady.

Authors:  Mahesh Krishnamurthy; Julieanna Jad Sahouria; Ravi Desai; Juanito Caguiat
Journal:  J Am Geriatr Soc       Date:  2004-10       Impact factor: 5.562

Review 2.  Cytotoxic chemotherapy for advanced or recurrent cervical cancer.

Authors:  J A Green; G Lainakis
Journal:  Ann Oncol       Date:  2006-09       Impact factor: 32.976

3.  Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel.

Authors:  Jing Li; Ling Chen; Qiuli Liu; Mei Tang; Yuan Wang; Jinjin Yu
Journal:  Cancer Biol Ther       Date:  2018-02-27       Impact factor: 4.742

4.  Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.

Authors:  Toran Sanli; Ayesha Rashid; Caiqiong Liu; Shane Harding; Robert G Bristow; Jean-Claude Cutz; Gurmit Singh; James Wright; Theodoros Tsakiridis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-07       Impact factor: 7.038

5.  [Lactic acidosis in diabetics on biguanides (author's transl)].

Authors:  P Wittmann; M Haslbeck; W Bachmann; H Mehnert
Journal:  Dtsch Med Wochenschr       Date:  1977-01-07       Impact factor: 0.628

6.  Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.

Authors:  Rabbie K Hanna; Chunxiao Zhou; Kimberly M Malloy; Li Sun; Yan Zhong; Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

Review 7.  Biguanides and NIDDM.

Authors:  C J Bailey
Journal:  Diabetes Care       Date:  1992-06       Impact factor: 19.112

8.  In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

Authors:  Walter H Gotlieb; Julio Saumet; Marie-Claude Beauchamp; Jing Gu; Susie Lau; Michael N Pollak; Ilan Bruchim
Journal:  Gynecol Oncol       Date:  2008-05-21       Impact factor: 5.482

9.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

10.  Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Authors:  Carminia Maria Della Corte; Vincenza Ciaramella; Concetta Di Mauro; Maria Domenica Castellone; Federica Papaccio; Morena Fasano; Ferdinando Carlo Sasso; Erika Martinelli; Teresa Troiani; Ferdinando De Vita; Michele Orditura; Roberto Bianco; Fortunato Ciardiello; Floriana Morgillo
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.